ClinicalTrials.Veeva

Menu

Short Implants in Edentulous Mandible

U

Universitätsklinikum Hamburg-Eppendorf

Status

Unknown

Conditions

Edentulous Jaw
Tooth Loss

Treatments

Device: Dental Implants (Straumann Roxolid® / SLActive®)

Study type

Observational

Funder types

Other

Identifiers

NCT04838184
PV_4805

Details and patient eligibility

About

Main aim of this study was to assess survival rates of short implants with a length of 4 mm in the edentulous mandible after 1, 3, and 5 years.

Full description

It is hypothesized that survival rates after 1, 3, and 5 years of Straumann Roxolid® / SLActive® 4 mm short implants do not differ from values of Straumann SLActive implants with more than 4 mm length in the same clinical situation.

Enrollment

20 patients

Sex

All

Ages

18 to 70 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

General criteria:

  • Age: 18 to 70
  • Edentulous mandible with reduced bone level in the posterior region (> 5 mm and < 8 mm above nerve conduit)
  • Physical and mental condition that allow surgery and a 5-year follow-up period to be carried out without foreseeable problems
  • Obtained informed consent from the patient

Specific criteria:

  • Limited vertical space for implant placement, where conventional implants with lengths of more than 4 mm cannot be used
  • Tooth loss or extraction at least 8 weeks before implant surgery
  • Healthy implantation site
  • Favorable and stable occlusal relationship
  • Complete denture in the mandible. If no denture available, an interims prosthesis will be fitted
  • Natural full dentition or sufficient complete or partial dentures in the maxilla

Exclusion criteria

General criteria:

  • Any conditions or circumstances which would interfere with the requirements for oral surgery
  • Allergy to any metallic implant component
  • Acute, untreated periodontitis
  • Previous oro-maxillo-facial radiotherapy
  • Any disorders in the planned implant area such as previous tumors or chronic bone disease (e.g., rheumatoid disease)
  • Any ongoing application of interfering medication (steroid therapy, bisphosphonate, etc.)
  • Alcohol or drug abuse
  • Heavy smoking (>10 cigarettes/day)
  • Uncontrolled diabetes
  • Severe bruxism or other destructive oral habits
  • Pregnant or lactating women

Specific criteria:

  • Need for a major bone regeneration technique
  • Infections in adjacent tissue of the planned implantation site.
  • Bleeding on probing (BOP) and plaque index (PI) higher 25%
  • Insufficient bone volume in the posterior region for placing a Straumann Roxolid® / SLActive® 4mm short implant and in the interforaminal region for placing a Straumann Roxolid® / SLActive® implant with a minimum length of 10 mm determined by radiographic analysis (OPG)

Trial design

20 participants in 1 patient group

Dental patients
Description:
Patients with an edentulous mandible who are demanding and receiving an implant-supported fixed dental prosthesis in the mandible
Treatment:
Device: Dental Implants (Straumann Roxolid® / SLActive®)

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems